TFPI — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL13402784	0.51	9/20
SCHEMBL7331095	0.60	7/20
SCHEMBL10014822	0.56	7/20
SCHEMBL13487335	0.54	7/20
SCHEMBL9107578	0.75	6/20
SCHEMBL9070287	0.65	6/20
SCHEMBL11932912	0.64	6/20
SCHEMBL13028816	0.62	6/20
SCHEMBL13086160	0.59	6/20
SCHEMBL12038596	0.58	6/20
SCHEMBL12038559	0.57	6/20
SCHEMBL9807262	0.56	6/20
SCHEMBL12038621	0.56	6/20
SCHEMBL9807268	0.55	6/20
SCHEMBL13086004	0.55	6/20
SCHEMBL9807252	0.55	6/20
SCHEMBL9807306	0.55	6/20
Angiotensin Amide (SCHEMBL7759731)	0.54	6/20
SCHEMBL12984358	0.53	6/20
SCHEMBL9807269	0.53	6/20

Clinical trials — most relevant to TFPI by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Comparative Evaluation of the Performance of Different Thromboplastin Reagents on Prothrombin Time in Situations of Isolated Extrinsic Pathway Factor Deficiency or Liver Damage	PHASE4	NOT_YET_RECRUITING
Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography	PHASE4	UNKNOWN
Vorapaxar on Thrombin Generation and Coagulability	PHASE4	COMPLETED
Study of TAK-672 in Participants With Acquired Hemophilia A	PHASE2/PHASE3	COMPLETED
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors	PHASE3	ACTIVE_NOT_RECRUITING
Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes	PHASE2	COMPLETED
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome	PHASE1	COMPLETED
Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Subcutaneous Single Dose	PHASE1	COMPLETED
Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Intravenous Administration	PHASE1	COMPLETED
Bioequivalence Study of a Generic Enoxaparin Sodium to Clexane® After Single Subcutaneous Dose in Healthy Human Subjects	PHASE1	COMPLETED
The Effect of Simvastatin Therapy on the Expression of Procoagulant and Inflammatory Markers in Heart Failure	EARLY_PHASE1	COMPLETED
Tissue Factor Expression in Stage C Heart Failure	nan	COMPLETED
Monitoring of Anti-TFPI in Hemophilia	nan	RECRUITING
Intensive Dose Tinzaparin in Hospitalized COVID-19 Patients	nan	UNKNOWN
Heparin Management During Cardiopulmonary Bypass in Children	nan	COMPLETED
Factor XI Levels in Acute Ischemic Stroke	nan	COMPLETED
Heparin or Enoxaparin in Patients With Cancer	nan	COMPLETED
Stroke Risk Assessment and Markers of Blood Clotting in Patients With Newly Diagnosed Non-valvular Atrial Fibrillation (NVAF), Who Have Not Received Oral Anticoagulation Therapy (OAC-therapy) Prior to Inclusion	nan	RECRUITING
Correlation Between PT and INR to Factor 7	nan	UNKNOWN
Targeting TFPI With Concizumab to Improve Haemostasis in Glanzmann Thrombasthenia Patients: an in Vitro Study	nan	COMPLETED
Influence of Rivaroxaban for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic PAD	nan	UNKNOWN
Genetic Epidemiology of Venous Thromboembolism	nan	COMPLETED
Haemostasis Management of Abdominal Aortic Procedures	nan	UNKNOWN
TFPI Levels in Haemophilia A and B Patients	nan	UNKNOWN
Thrombin Regulated Platelet Activation	nan	COMPLETED
Effects of the Bone Tissue on the Haemostasis	nan	UNKNOWN
Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia	nan	COMPLETED
Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)	nan	COMPLETED
Diagnostic Accuracy Study of a Point-of-Care Test for Coagulation Function	nan	UNKNOWN
Comparative Evaluation of the Performance of Different Thromboplastin Reagents on Prothrombin Time and Factorial Assays in Situations of Isolated Extrinsic Pathway Factor Deficiency or Liver Damage.	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a TFPI binder may also engage these)

Protein	Name	Similarity
Q28864	—	1.000	Q28864 →
P19761	—	0.995	P19761 →
Q02445	—	0.995	Q02445 →
Q7YRQ8	—	0.992	Q7YRQ8 →
O54819	—	0.992	O54819 →
B5M0W4	—	0.988	B5M0W4 →
P0DN15	—	0.987	P0DN15 →
TFPI2	Tissue factor pathway inhibitor 2	0.984	landscape →
F5GTK6	—	0.983	F5GTK6 →
O62247	—	0.983	O62247 →
P0DN16	—	0.983	P0DN16 →
P0DN12	—	0.983	P0DN12 →
W4VSH9	—	0.982	W4VSH9 →
Q8MVC4	—	0.982	Q8MVC4 →
C0HMD5	—	0.982	C0HMD5 →
P04815	—	0.982	P04815 →
P0DN13	—	0.981	P0DN13 →
O35536	—	0.981	O35536 →
P00974	—	0.981	P00974 →
Q9R097	—	0.980	Q9R097 →
P0DN17	—	0.980	P0DN17 →
P86855	—	0.980	P86855 →
SPINT2	Kunitz-type protease inhibitor 2	0.980	landscape →
P0DN06	—	0.980	P0DN06 →
B2BS84	—	0.980	B2BS84 →
P49223	—	0.980	P49223 →
O62845	—	0.980	O62845 →
Q6UDR6	—	0.980	Q6UDR6 →
P0DN10	—	0.979	P0DN10 →
P0DN11	—	0.979	P0DN11 →